Board Committee Changes

30 September 2022 10:30 BST

Remuneration Committee Chair Appointment

AstraZeneca PLC today announced the appointment of Sheri McCoy, Non-Executive Director, as Chair of the Remuneration Committee.  Sheri has served as a member of the Remuneration Committee since July 2018.

Sheri will succeed Michel Demaré who will step down as Chair of the Remuneration Committee following his recent appointment as Chair-designate of the Board.  He will remain a member of the Committee.

Sheri will also become a member of the Nomination and Governance Committee.

These Remuneration Committee and Nomination and Governance Committee changes are effective from 1 December 2022.  As previously announced, Michel Demaré will become Chair of the Board at the end of the Company's Annual General Meeting in April 2023.

Notes

Biography and photograph:
https://www.astrazeneca.com/our-company/leadership.html#board

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp
Company Secretary
AstraZeneca PLC
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.